Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion/dextromethorphan - Axsome Therapeutics

Drug Profile

Bupropion/dextromethorphan - Axsome Therapeutics

Alternative Names: AXS-05; Dextromethorphan/bupropion; Dextromethorphan/bupropion modulated delivery tablet

Latest Information Update: 16 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Developer Axsome Therapeutics; Duke University
  • Class Anti-inflammatories; Antidepressants; Morphinans; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder
  • Phase II/III Agitation
  • Phase II Smoking withdrawal

Most Recent Events

  • 14 Sep 2020 Updated efficacy data from the phase III GEMINI trial in Major depressive disorder released by Axsome Therapeutics
  • 31 Aug 2020 Axsome Therapeutics announces intention to submit NDA for bupropion/dextromethorphan in Agitation (AD agitation)
  • 31 Aug 2020 Axsome Therapeutics completes Breakthrough Therapy meeting with the US FDA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top